

AB012. Transcriptional and chromatin profiling reveals the molecular architecture and druggable vulnerabilities of thymic epithelial tumors (TETs)

Pierluigi Giuseppe Manti^{1,2}, Sebastiano Trattaro^{1,2},
 Roberta Ragazzini^{3,4}, Davide Castaldi^{1,2,5},
 Gianluca Vozza^{1,2}, Giovanni Bertalot¹,
 Sude Beskardes¹, Erika Tenderini¹,
 Asllan Gijnovci^{3,4}, Martina Pezzali^{1,2,5},
 Luca Molinaro⁶, Diana Sporic⁷, Luca Marelli¹,
 Carlo Emanuele Villa^{1,5}, Salvatore Pece^{1,2},
 Mauro Giulio Papotti⁸, Enrico Ruffini⁹,
 Lorenzo Spaggiari^{1,2}, Paola Bonfanti^{3,4,10},
 Giuseppe Testa^{1,2,5}

¹Department of Experimental Oncology, IEO, European Institute of Oncology, IRCCS, Milan, Italy; ²Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy; ³Epithelial Stem Cell Biology & Regenerative Medicine Laboratory, The Francis Crick Institute, London, UK; ⁴Institute of Immunity & Transplantation, Division of Infection & Immunity, UCL, Royal Free Hospital, London, UK; ⁵Human Technopole, Milan, Italy; ⁶A.O.U. Città della Salute e della Scienza Hospital, Division of Pathology, Turin, Italy; ⁷Department of Oncology, University of Turin, Turin, Italy; ⁸Department of Oncology, Division of Pathology, University of Turin, Turin, Italy; ⁹Department of Thoracic Surgery, University of Turin, Turin, Italy; ¹⁰UCL Great Ormond Street Institute of Child Health, London, UK

Correspondence to: Pierluigi Giuseppe Manti. Department of Oncology and Hemato-Oncology, University of Milan, Via Festa del Perdono 7, Milan, Italy. Email: pierluigi.manti@ieo.it.

Abstract: Thymic epithelial tumors (TETs) have been profiled to the present moment mainly through several analyses of FFPE samples. Despite the leap forward brought by the TCGA, several questions remain still unsolved. Among these, TETs are characterized by a strong component of immune infiltrate which makes the transcriptomic analyses conducted so far scarcely interpretable to profile stromal subpopulations constitutive of the tumor. Furthermore, rarely correspondent healthy

tissue is available due to the lipomatous atrophy of aged thymi. Therefore, the recent report of (I) isolation, (II) propagation (III) and characterization of human thymic epithelial cells (TECs) and their capacity to reconstitute the functional organ ex vivo and in vivo, represents a novel approach to study the biology of both healthy and neoplastic thymi. Human thymic biopsies (both healthy and neoplastic) were digested and plated on a lethally irradiated murine feeder layer. Both RNA-Seq and CUTANDTAG were performed on cultivated TECs at different passages. Cultured TECs were injected with human thymic interstitial cells into rat decellularized scaffolds and cultivated for 10–12 days. sc-RNA Seq is currently being performed on both healthy and neoplastic thymic mini-organs and their correspondent primary tissues. Here show that we successfully cultivated a cohort of 21 clonogenic TECs in vitro including adult neoplastic TECs, their non-tumoral counterpart and pediatric TECs. We show that at the transcriptome level each class of TECs clusters independently and that neoplastic TECs belong to the same cloud independently from thymoma histotype. Around 1,400 differentially expressed genes (DEGs) can be found when comparing adult neoplastic and non-neoplastic counterpart, among which around 70 are transcription factors. Importantly, we prove for the first time that clonogenic TECs derived from TETs can repopulate a decellularized rat scaffold and recreate a 3D architecture mimicking the primary tumor. This work demonstrates that this culture system allows the expansion of clonogenic TECs from both tumor samples and their non-tumoral counterpart. Those cells, when transplanted into decellularized thymi, reproduce the architecture of the primary tissue, showing that TETs contain progenitor/stem epithelial cells. We are currently characterizing TECs at the transcriptomic and epigenomic level with aim of identifying new druggable targets prior to clinical trials.

Keywords: Thymoma; thymic epithelial cells (TECs); miniorgan; stem cells

Acknowledgments

Funding: None.

Footnote

Conflicts of Interest: PB and AG are named inventors of patent application No. PCT/GB2019/051310. The other

authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the

original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: <https://creativecommons.org/licenses/by-nc-nd/4.0/>.

doi: 10.21037/med.2021.ab012

Cite this abstract as: Manti PG, Trattaro S, Ragazzini R, Castaldi D, Vozza G, Bertalot G, Beskardes S, Tenderini E, Gijnovci A, Pezzali M, Molinaro L, Sporici D, Marelli L, Villa CE, Pece S, Papotti MG, Ruffini E, Spaggiari L, Bonfanti P, Testa G. Transcriptional and chromatin profiling reveals the molecular architecture and druggable vulnerabilities of thymic epithelial tumors (TETs). *Mediastinum* 2021;5:AB012.